AstraZeneca has entered an R&D pact with Silence Therapeutics in the respiratory field. Silence will receive initial access fees, clinical development and commercial milestone payments as much as $400 million, plus royalties on product sales. The three-year collaboration is designed to discover and develop proprietary siRNA molecules against as many as five specific targets provided by AZ. The companies will collaborate in the early phase of identification and optimisation of novel siRNA ...